Printer Friendly

Schering-Plough's TEMODAL Capsule for Glioblastoma Multiforme Granted Priority Review by Government.

Tokyo, Japan, Nov 2, 2005 - (JCNN) - Schering-Plough K.K. has announced that the Ministry of Health, Labor and Welfare (MHLW) has granted the company with a priority review status for TEMODAL Capsule, an antitumor agent imported by Schering-Plough. TEMODAL (temozolomide) Capsule is an oral, cytotoxic alkylating agent indicated for treating glioblastoma multiforme (GBM).

In Japan, it is estimated that about 2,500 people develop GBM annually, of whom about 2,200 people are diagnosed as anaplastic astrocytoma.

Initially approved in the EU in January 1999, temozolomide is currently approved in 77 countries worldwide.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:1USA
Date:Nov 2, 2005
Words:109
Previous Article:Kaken Pharmaceutical to Outsource Entire Distribution Operation to Itochu.
Next Article:National Institute of Technology and Evaluation, Astellas Pharma, Chugai Pharmaceutical to Collaborate in Searching Microorganisms in Vietnam.
Topics:


Related Articles
BRITISH BIOTECH SAYS MARIMASTAT OFFERS NO BENEFITS.
BRAIN CANCER DRUG GETS ORPHAN DRUG DESIGNATION FROM EMEA.
MIGENIX INITIATES ENROLLMENT IN PHASE IIB HEPATITIS TRIAL.
Jones Lang LaSalle is tapped for global assignment by drug giant.
Drug giant taps Jones Lang LaSalle for RE services.
Schering-Plough fined for off-label marketing, overcharging, kickbacks.
Schering-Plough.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters